IL146003A0 - USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION - Google Patents

USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Info

Publication number
IL146003A0
IL146003A0 IL14600300A IL14600300A IL146003A0 IL 146003 A0 IL146003 A0 IL 146003A0 IL 14600300 A IL14600300 A IL 14600300A IL 14600300 A IL14600300 A IL 14600300A IL 146003 A0 IL146003 A0 IL 146003A0
Authority
IL
Israel
Prior art keywords
adrenergic receptor
sexual dysfunction
selective antagonists
improvement
sub
Prior art date
Application number
IL14600300A
Other languages
English (en)
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Publication of IL146003A0 publication Critical patent/IL146003A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
IL14600300A 1999-05-07 2000-05-08 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION IL146003A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI000995A IT1312310B1 (it) 1999-05-07 1999-05-07 Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
PCT/EP2000/004308 WO2000067735A2 (en) 1999-05-07 2000-05-08 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Publications (1)

Publication Number Publication Date
IL146003A0 true IL146003A0 (en) 2002-07-25

Family

ID=11382912

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14600300A IL146003A0 (en) 1999-05-07 2000-05-08 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Country Status (25)

Country Link
US (2) US6303606B1 (pl)
EP (1) EP1177190B1 (pl)
JP (1) JP2002544158A (pl)
KR (1) KR100696755B1 (pl)
CN (1) CN1150187C (pl)
AT (1) ATE308538T1 (pl)
AU (1) AU765487B2 (pl)
BR (1) BR0010348A (pl)
CA (1) CA2366201A1 (pl)
DE (1) DE60023686T2 (pl)
DK (1) DK1177190T3 (pl)
ES (1) ES2250130T3 (pl)
HK (1) HK1039900B (pl)
HU (1) HUP0201184A3 (pl)
IL (1) IL146003A0 (pl)
IT (1) IT1312310B1 (pl)
MX (1) MXPA01011261A (pl)
NO (1) NO321841B1 (pl)
NZ (1) NZ515240A (pl)
PL (1) PL196708B1 (pl)
RU (1) RU2239633C2 (pl)
SI (1) SI1177190T1 (pl)
TW (1) TWI224503B (pl)
WO (1) WO2000067735A2 (pl)
ZA (1) ZA200110042B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
CA2538415A1 (en) * 2003-09-15 2005-03-24 Wilfred Wayne Lautt Use of antagonists of hepatic sympathetic nerve activity
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005112889A2 (en) * 2004-05-20 2005-12-01 Recordati Ireland Limited Transmucosal delivery formulations
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
NZ554183A (en) * 2004-10-18 2009-04-30 Polymun Scient Immunbio Forsch Liposomal composition comprising an active ingredient for relaxing smooth muscle production and therapeutically use of said composition
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CN104721168A (zh) 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
CN101592613B (zh) * 2009-07-06 2011-12-21 广东省药品检验所 一种中成药、保健食品和食品中添加pde5型抑制剂的检测方法
SG188402A1 (en) 2010-09-13 2013-04-30 Otsuka Pharma Co Ltd Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.
JP6415982B2 (ja) * 2012-03-12 2018-10-31 大塚製薬株式会社 複素環化合物
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
ES2625548T3 (es) 2012-06-04 2017-07-19 DiaMedica Therapeutics Inc. Isoformas de glicosilación de la calicreína-1 tisular humana
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3939591A1 (en) 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CA3054962A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
TW213903B (pl) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
ATE190843T1 (de) 1993-02-10 2000-04-15 Bmra Corp Bv Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
DE814775T1 (de) 1995-03-14 1998-06-25 Vivus Inc Methode und kit zur verhütung erektiler dysfunktion
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
JPH11512710A (ja) 1995-09-29 1999-11-02 メルク エンド カンパニー インコーポレーテッド アルファ１ｂアドレナリンレセプターアンタゴニスト
US5700364A (en) 1995-10-30 1997-12-23 Merck & Co., Inc. Electrochemical oxidation
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
EP1027054A4 (en) * 1997-10-28 2002-11-04 Vivus Inc LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION

Also Published As

Publication number Publication date
ES2250130T3 (es) 2006-04-16
ZA200110042B (en) 2002-07-02
IT1312310B1 (it) 2002-04-15
TWI224503B (en) 2004-12-01
BR0010348A (pt) 2002-02-13
JP2002544158A (ja) 2002-12-24
WO2000067735A2 (en) 2000-11-16
KR20020002494A (ko) 2002-01-09
HK1039900A1 (en) 2002-05-17
HUP0201184A2 (en) 2002-10-28
EP1177190B1 (en) 2005-11-02
US6303606B1 (en) 2001-10-16
MXPA01011261A (es) 2002-08-12
DE60023686T2 (de) 2006-07-20
US20020161009A1 (en) 2002-10-31
HUP0201184A3 (en) 2003-05-28
EP1177190A2 (en) 2002-02-06
KR100696755B1 (ko) 2007-03-19
ATE308538T1 (de) 2005-11-15
HK1039900B (en) 2006-02-03
PL196708B1 (pl) 2008-01-31
SI1177190T1 (sl) 2006-02-28
NO20015428D0 (no) 2001-11-06
PL351624A1 (en) 2003-05-19
NZ515240A (en) 2003-09-26
NO321841B1 (no) 2006-07-10
NO20015428L (no) 2001-11-06
AU4565400A (en) 2000-11-21
AU765487B2 (en) 2003-09-18
CN1150187C (zh) 2004-05-19
DK1177190T3 (da) 2006-02-20
CN1354749A (zh) 2002-06-19
WO2000067735A3 (en) 2001-02-01
DE60023686D1 (de) 2005-12-08
ITMI990995A1 (it) 2000-11-07
RU2239633C2 (ru) 2004-11-10
US6953800B2 (en) 2005-10-11
CA2366201A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
IL146003A0 (en) USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
EP1027011A4 (en) ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
NZ336436A (en) Solid dosage forms and method for ameliorating male erectile dysfunction
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
IL172833A0 (en) Pyrimidine-2,4-dione derivatives and pharmaceutical compositions containing the same
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
AU1192302A (en) Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
TNSN00199A1 (fr) PYRAZOLO [4,3-d] PYRIMIDINES-7-ONES PHARMACEUTIQUEMENT ACTIVES, LEUR PREPARATION ET MEDICAMENTS LES CONTENANT
IL153297A0 (en) Compounds and compositions for delivering active agents
MY133423A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
UA41316C2 (uk) Трициклічні похідні піролу і фармацевтичний препарат
PL347671A1 (en) Compounds and compositions for delivering active agents
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
PL360254A1 (pl) Kompozycja farmaceutyczna
ATE428427T1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
BG106602A (en) Formulation of substituted benzimidazoles
ZA200007019B (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence.
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
NZ512137A (en) Prostaglandin E2 (PGE2) and PGE4 analogues, which are antagonists of the EP2 receptor for treatment of female sexual dysfunction
MXPA03004547A (es) Agonistas receptores de d4 de dopamina selectivos para el tratamiento de disfuncion sexual.
AU2003226765A8 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
MXPA03003481A (es) Tratamiento de disfuncion sexual utilizando antagonista de bombesina.
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction